Owner evaluation of quality of life and mobility in osteoarthritic cats treated with amantadine or placebo

Hilary Shipley, Kristi Flynn, Laura Tucker, Erin L Wendt Hornickle, Caroline F Baldo, Daniel Almeida, Sandra Allweiler, Alonso Guedes

Research output: Contribution to journalArticlepeer-review


Objectives: The aim of the study was to determine if amantadine improves owner-identified mobility impairment and quality of life associated with osteoarthritis in cats. Methods: Using a blinded, placebo-controlled, randomized, crossover design, 13 healthy client-owned cats with clinical and radiographic evidence of osteoarthritis and owner-identified mobility impairment were studied. Cats received 5 mg/kg amantadine or placebo q24h PO for 3 weeks each with no washout period between. Locomotor activity was continuously assessed with a collar-mounted activity monitor system, and owners chose and rated two mobility-impaired activities using a client-specific outcome measures (CSOM) questionnaire on a weekly basis. Locomotor activity on the third treatment week was analyzed with two-tailed paired t-tests. The CSOM scores were analyzed using a mixed-effect model and the Bonferroni post-hoc test. Owner-perceived changes in quality of life were compared between treatments using the χ2 test. Statistical significance was set at P <0.05. Results: Mean ± SD activity counts during the third week of each treatment were significantly lower with amantadine (240,537 ± 53,880) compared with placebo (326,032 ± 91,759). CSOM scores assigned by the owners were significantly better with amantadine on the second (3 ± 1) and third (3 ± 1) weeks compared with placebo (5 ± 2 and 5 ± 1, respectively). A significantly greater proportion of owners reported improvement in quality of life with amantadine compared with placebo. Conclusions and relevance: Amantadine significantly decreased activity, but improved owner-identified impaired mobility and owner-perceived quality of life in cats with osteoarthritis. Amantadine appears to be an option for the symptomatic treatment of osteoarthritis in cats.

Original languageEnglish (US)
JournalJournal of Feline Medicine and Surgery
StateAccepted/In press - 2020

Bibliographical note

Funding Information:
This study was supported by the Small Companion Animal Research Grants, College of Veterinary Medicine, University of Minnesota.


  • analgesia
  • chronic pain
  • Degenerative joint disease
  • musculoskeletal

PubMed: MeSH publication types

  • Journal Article

Fingerprint Dive into the research topics of 'Owner evaluation of quality of life and mobility in osteoarthritic cats treated with amantadine or placebo'. Together they form a unique fingerprint.

Cite this